Obesity and hypertension

December 04, 2014

The link between obesity and cardiovascular diseases is well acknowledged. Being obese or overweight is a major risk factor for the development of elevated blood pressure, and cardiovascular diseases. But it has net been known how obesity increases the risk of high blood pressure, making it difficult to develop evidence based therapies for obesity, hypertension and heart disease.

In a ground-breaking study, published today in the prestigious journal, Cell (embargo midday EST), researchers from Monash University in Australia, Warwick, Cambridge in the UK and several American universities have discovered the link between obesity and hypertension. This research has discovered that the hormone leptin which is secreted by fat cells is significantly elevated following weight gain and in obesity, acts in the brain to elevate blood pressure. These studies, involve both animal and human experiments, including a unique cohort of patients lacking the hormone leptin or lacking the leptin receptor. Results demonstrated that both blocking leptin from producing its actions in the brain and removal of the leptin receptors, from the brain were effective at for the reducing obesity induced hypertension. As much as 80% of common hypertension is caused by excess body fat, and this study for the first time describes the mechanism by which obesity elevates blood pressure, and opens up new approaches to treat obesity induced high blood pressure.

The study - led by Professor Michael Cowley, Director of the Monash Obesity & Diabetes Institute within the School of Biomedical Sciences, Monash University, Australia - used a number of new and unique technologies to link leptin in obesity induced hypertension:"This study shows that a hormone secreted by fat (leptin) increases blood pressure, and explains the mechanism of the known link between obesity and high blood pressure."

"Our data suggest that pharmacological approaches based on altering the effect of leptin in the dorsomedial hypothalamic region of the brain, could potentially represent a therapeutic target for the treatment of obesity induced hypertension and potentially could be exploited to alleviate the incidence of obesity induced cardiovascular diseases."

The researchers are now investigating whether blocking the leptin receptor may be a way to reduce the incidence of hypertension and cardiovascular diseases in obesity. The anti-hypertensive drug market is expected to exceed $40 billion annually by 2018.
-end-
*World Preview 2018 report by Evaluate Pharma.

Tania Ewing and Associates

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.